Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

NCT03121625 is registered in ClinicalTrials.gov with Hebei Senlang Biotechnology Inc., Ltd. as lead sponsor.

NCT NCT03121625
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03121625 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
Lead sponsor
Hebei Senlang Biotechnology Inc., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
December 26, 2016
Completion date
December 31, 2021
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphoma